Jaguar Report
11th May 2022
TAG Investment Bankers is pleased to announce today publication of a research report into Jaguar Health Inc (NASDAQ: JAGX), which is a healthcare company listed in the USA that specialises in non- opioid gastrointestinal remedies not only for humans but also animals. Its key drugs in these two areas are Mytesi® and Canalevia® respectively. The report states that fair value for the shares is up to US$11.60, using a net present value approach, compared with yesterday's US$0.40 closing price.
Currently, Mytesi is Jaguar Health, Inc.’s (‘Jaguar’) (NASDAQ: JAGX) core growth driver and the company revealed a strong start to the current financial year in its Q1 numbers, which showed a better than market expectations 111.5% increase in net product revenue. However, there is substantially more to Jaguar than the current commercial performance of its flagship drug, Mytesi (crofelemer, a first in class anti-secretory agent).
The company’s crofelemer product pipeline, and revenue and earnings potential should all benefit from a number of significant new developments in 2022, which tend to argue for a higher valuation. Moreover, there is potential to add shareholder value through the possible receipt of a priority review voucher for the company’s lechlemer drug product candidate and from equity participation in an Italian licensee of crofelemer, Napo Therapeutics.
Mytesi appears well placed to deliver significant growth and generate substantial shareholder value in its core indication of HIV related diarrhea. The drug boasts a robust proof of concept and is poised to be a prime beneficiary of Jaguar’s three enhanced route-to-market plans for the current financial year. Moreover Mytesi, which reported a strong FY2022 Q1 sales number, was largely responsible for Jaguar beating the market’s earnings expectations in the period.
Contact
Chris Wickham
Chief Marketing Officer
TAG Investment Bankers Ltd
Email: Chris.wickham@tagbankers.com
Tel: +4477 6465 5390
Please refer to the research report’s disclaimer which is copied in full on page 2 of this Press Release.
Disclaimer
Jaguar Health, Inc. paid TAG Investment Bankers Ltd analyst Chris Wickham US$10,000 to produce this report. Fees are paid up front without recourse. This report has been published by TAG Investment Bankers Ltd. TAG Investment Bankers Ltd do not offer personal advice, and the information referred to on our sites is not suitable for all investors. You confirm that you are a person falling within the following categories of an appropriately qualified investor and are therefore exempt from the general restriction on the communication of invitations or inducements to engage in investment activity on the grounds that you are, either a high net worth individual, a sophisticated investor, an Investment Professional or a representative of a high net worth company, trust, partnership or association. If you are unsure whether an investment is suitable for your circumstances we strongly encourage you to consult an FCA/SEC or other Financial Regulator in your country of residence – authorized Independent Financial Adviser before committing to any form of investment. Opinions contained in this report represent those of TAG Investment Bankers Ltd at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.
All information and numbers are subject to change without notice. Any return on investment stated is for discussion purposes only and is based on a best efforts basis. Under no circumstances whatsoever does it represent a fair and accurate view of actual results. Please be advised that it will change or might change in the future and that under no circumstances whatsoever can we or any of our associates, employees or partners be held responsible if the forecasted results are not met.